Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.

The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has provoked considerable interest over recent years as a novel therapeutic target in cancer. A brief outline of the IGF-1R signalling system and the rationale for its use in cancer medicine is given. This is followed by a discussion of the different possible targets within the IGF-1R system, and drugs developed to interact at each target. A systems-based approach is then used to review the in vitro and in vivo data in the published literature of the following compounds targeting IGF-1R components using specific examples: growth hormone releasing hormone antagonists (e.g. JV-1-38), growth hormone receptor antagonists (e.g. pegvisomant), IGF-1R antibodies (e.g. CP-751,871, AVE1642/EM164, IMC-A12, SCH-717454, BIIB022, AMG 479, MK-0646/h7C10), and IGF-1R tyrosine kinase inhibitors (e.g. BMS-536942, BMS-554417, NVP-AEW541, NVP-ADW742, AG1024, potent quinolinyl-derived imidazo (1,5-a)pyrazine PQIP, picropodophyllin PPP, Nordihydroguaiaretic acid Insm-18/NDGA). The following tumour types are specifically discussed: lung, breast, colorectal, pancreatic, NETs, sarcoma, prostate, leukaemia, multiple myeloma. Other tumour types are mentioned briefly: squamous cell carcinoma of the head and neck, melanoma, glioblastoma, ovary, gastric and mesothelioma. Results of early stage clinical trials, involving recently patented drugs. are included where appropriate. We then outline the current understanding of toxicity related to IGF-1R targeted therapy, and finally outline areas for further research.

[1]  Ken Kato,et al.  Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer , 2008, Oncology.

[2]  R. Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .

[3]  R. Nahta,et al.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling (Molecular Cancer Therapeutics (2007) 6, (667-674)) , 2008 .

[4]  R. Fonseca,et al.  Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Takahashi,et al.  Bcr-Abl induces autocrine IGF-1 signaling , 2008, Oncogene.

[6]  V. Macaulay,et al.  Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer , 2008 .

[7]  O. Larsson,et al.  Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1 , 2008, Oncogene.

[8]  A. Chakraborty,et al.  Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. , 2008, Cancer research.

[9]  J. Wallace,et al.  Structure and functional analysis of the IGF‐II/IGF2R interaction , 2008, The EMBO journal.

[10]  I. Modlin,et al.  Neuroendocrine tumors of the diffuse neuroendocrine system , 2008, Current opinion in oncology.

[11]  R. Nicholson,et al.  Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance , 2008, Breast Cancer Research and Treatment.

[12]  P. Richardson,et al.  From the bench to the bedside: emerging new treatments in multiple myeloma. , 2007 .

[13]  M. Boccadoro,et al.  Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma. , 2007 .

[14]  Christilyn P. Graff,et al.  BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy , 2007 .

[15]  O. Larsson,et al.  Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival , 2007, International journal of cancer.

[16]  J. Bourhis,et al.  Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer , 2007, Nature Clinical Practice Oncology.

[17]  A. Adjei,et al.  Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.

[18]  R. Salazar,et al.  New drug development in digestive neuroendocrine tumors. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  N. Gibson,et al.  A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo , 2007, Molecular Cancer Therapeutics.

[20]  A. Arcaro,et al.  Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway , 2007, Leukemia.

[21]  A. Gualberto,et al.  Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients , 2007 .

[22]  Xia Han,et al.  Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor , 2007 .

[23]  C. Higano,et al.  A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors , 2007 .

[24]  A. Tolcher,et al.  A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer , 2007 .

[25]  L. Paz-Ares,et al.  Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) , 2007 .

[26]  Edward S. Kim,et al.  Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib , 2007, Clinical Cancer Research.

[27]  M. Slomiany,et al.  Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. , 2007, Cancer letters.

[28]  D. English,et al.  Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[29]  J. McCubrey,et al.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion , 2007, Leukemia.

[30]  A. Belfiore.  The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. , 2007, Current pharmaceutical design.

[31]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[32]  E. Winer,et al.  Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.

[33]  R. Nahta,et al.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling , 2007, Molecular Cancer Therapeutics.

[34]  L. Schaaf,et al.  Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy , 2007, Clinical Cancer Research.

[35]  D. Aftab.  590 POSTER Simultaneous inhibition of IGF1R and Src family kinases causes tumor growth inhibition and tumor regression in xenograft models , 2006 .

[36]  A. H. Yeh,et al.  Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs , 2006, Oncogene.

[37]  Edward S. Kim,et al.  Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.

[38]  M. Lawrence,et al.  Structure of the insulin receptor ectodomain reveals a folded-over conformation , 2006, Nature.

[39]  D. Yee,et al.  Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. , 2006, The Annals of thoracic surgery.

[40]  M. Dowsett,et al.  Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? , 2006, British Journal of Cancer.

[41]  N. Mckern,et al.  The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity , 2006, Proceedings of the National Academy of Sciences.

[42]  Diane D. Liu,et al.  The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. , 2006, Cancer letters.

[43]  R. Nicholson,et al.  Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells , 2006, British Journal of Cancer.

[44]  F. Cappuzzo,et al.  Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Hisayuki Yokoyama,et al.  Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. , 2006, The Tohoku journal of experimental medicine.

[46]  A. Martins,et al.  Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor , 2006, Clinical Cancer Research.

[47]  H. Tsuda,et al.  Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer , 2006, Modern Pathology.

[48]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[49]  G. Mills,et al.  Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Stephen L. Abrams,et al.  Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells , 2006, Leukemia.

[51]  M. Slomiany,et al.  IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. , 2006, Biochemical and biophysical research communications.

[52]  Adrian V. Lee,et al.  The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth , 2006, Breast Cancer Research and Treatment.

[53]  M. Höpfner,et al.  The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. , 2006, Endocrine-related cancer.

[54]  O. Larsson,et al.  The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  M. Pollak,et al.  Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[56]  D. Yee,et al.  Targeting insulin-like growth factor pathways , 2006, British Journal of Cancer.

[57]  O. Larsson,et al.  IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. , 2006, Blood.

[58]  C. Conover,et al.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.

[59]  A. Chakravarti,et al.  Radiation Enhances the Invasive Potential of Primary Glioblastoma Cells via Activation of the Rho Signaling Pathway , 2006, Journal of Neuro-Oncology.

[60]  I Farmer,et al.  The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. , 2005, Endocrine-related cancer.

[61]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[62]  D. Yee,et al.  Type I insulin-like growth factor receptor as a therapeutic target in cancer. , 2005, Cancer research.

[63]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[64]  Francesco Hofmann,et al.  Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. , 2005, Drug discovery today.

[65]  R. Baserga.  The insulin-like growth factor-I receptor as a target for cancer therapy , 2005, Expert opinion on therapeutic targets.

[66]  J. Baselga,et al.  Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy , 2005 .

[67]  P. Picci,et al.  Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. , 2005, European journal of cancer.

[68]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[69]  H. Yi,et al.  Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. , 2005, Biochemical and biophysical research communications.

[70]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[71]  P. Lollini,et al.  Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. , 2005, Cancer research.

[72]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[73]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[74]  Nasser Peyghambarian,et al.  Electro-optic properties of hybrid solgel doped with a nonlinear chromophore with large hyperpolarizability. , 2005, Optics letters.

[75]  P. Pauwels,et al.  A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.

[76]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[77]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.

[78]  C. Shimizu,et al.  Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. , 2004, Human pathology.

[79]  T. Kurabayashi,et al.  Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. , 2004, Endocrinology.

[80]  J. Bourhis,et al.  Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation , 2004, British Journal of Cancer.

[81]  K. Shitara,et al.  Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors , 2004, Cancer Research.

[82]  F. Khuri,et al.  Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer , 2004, Oncogene.

[83]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[84]  M. Spitz,et al.  Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer , 2004, Clinical Cancer Research.

[85]  S. Helle.  The insulin-like growth factor system in advanced breast cancer. , 2004, Best practice & research. Clinical endocrinology & metabolism.

[86]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[87]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[88]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[89]  O. Larsson,et al.  Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth , 2004, Cancer Research.

[90]  M. Bouxsein,et al.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. , 2004, The Journal of clinical investigation.

[91]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[92]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[93]  A. Schally,et al.  Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. , 2003, Cancer research.

[94]  K. Pavelić,et al.  Gastric cancer: the role of insulin‐like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6‐P/IGF 2R) , 2003, The Journal of pathology.

[95]  A. Levitzki,et al.  Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics* , 2003, Journal of Biological Chemistry.

[96]  S. Monti,et al.  Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. , 2003, Anticancer research.

[97]  E. K. Maloney,et al.  An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. , 2003, Cancer research.

[98]  Domenico Coppola,et al.  Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.

[99]  D. Yee,et al.  A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. , 2003, Cancer research.

[100]  D. Bassi,et al.  Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. , 2003, The American journal of pathology.

[101]  A. Bajo,et al.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Martin Holzenberger,et al.  IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice , 2003, Nature.

[103]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[104]  L. Ellis,et al.  Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  H. Senn,et al.  Insulin-like growth factors and cancer. , 2002, The Lancet. Oncology.

[106]  P. Lollini,et al.  Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells , 2002, Cancer Gene Therapy.

[107]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[108]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[109]  Y Tenjin,et al.  Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. , 2001, Human cell.

[110]  J. Bourhis,et al.  Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells , 2001, British Journal of Cancer.

[111]  P. Darbre,et al.  Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[112]  Weiqun Li,et al.  Differential Requirement for Rho Family GTPases in an Oncogenic Insulin-like Growth Factor-I Receptor-induced Cell Transformation* , 2001, The Journal of Biological Chemistry.

[113]  J. Mendelsohn,et al.  Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody , 2001, Oncogene.

[114]  J. A. Scarlett,et al.  Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. , 2001, Journal of neurosurgery.

[115]  C. Potten,et al.  Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer , 2000, British Journal of Cancer.

[116]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[117]  D. Hanahan,et al.  Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. , 1999, The Journal of clinical investigation.

[118]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[119]  M. White,et al.  Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling , 1999, Nature Genetics.

[120]  G Nilsson,et al.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. , 1999, Cancer research.

[121]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[122]  C. Kahn,et al.  Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes , 1999, Cell.

[123]  B. Stoll.  Western nutrition and the insulin resistance syndrome: A link to breast cancer , 1999, European Journal of Clinical Nutrition.

[124]  M. Spitz,et al.  Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. , 1999, Journal of the National Cancer Institute.

[125]  P. Lollini,et al.  Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. , 1998, Cancer research.

[126]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[127]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[128]  R. Hardman,et al.  Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. , 1997, Cancer research.

[129]  G. Evan,et al.  Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis , 1997, Molecular and cellular biology.

[130]  P. Lønning,et al.  Influence of treatment with tamoxifen and change in tumor burden on the IGF‐system in breast cancer patients , 1996, International journal of cancer.

[131]  D. Carbone,et al.  Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. , 1996, Cancer research.

[132]  O. Larsson,et al.  Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. , 1996, Experimental cell research.

[133]  M. Korc,et al.  Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. , 1995, Cancer research.

[134]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[135]  P. Houghton,et al.  Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. , 1994, The Journal of clinical investigation.

[136]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[137]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[138]  C. Osborne,et al.  Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. , 1976, Proceedings of the National Academy of Sciences of the United States of America.